| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 03/22/2001 | WO1999063936A8 Novel therapeutic agents that modulate endothelin receptors |
| 03/22/2001 | CA2386559A1 Isolation of muscle-derived stem cells and uses therefor |
| 03/22/2001 | CA2385234A1 Nrage nucleic acids and polypeptides and uses thereof |
| 03/22/2001 | CA2384974A1 Compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 03/22/2001 | CA2384782A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | CA2384324A1 Proteins associated with cell differentiation |
| 03/22/2001 | CA2384294A1 Nicotinic acetylcholine receptor: alpha10 subunit |
| 03/22/2001 | CA2383360A1 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 03/22/2001 | CA2382633A1 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | CA2381252A1 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| 03/21/2001 | EP1085089A2 Human cyclic nucleotide phosphodiesterase |
| 03/21/2001 | EP1084122A1 Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity |
| 03/21/2001 | EP1083921A1 Novel leukotriene receptor antagonists and their uses |
| 03/21/2001 | EP1083917A1 Novel analgesic agents |
| 03/21/2001 | EP1083905A2 Selective estrogen receptor modulator in combination with dehydroepiandrosterone (dhea) or analogues |
| 03/21/2001 | EP1083893A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the d 1? receptors |
| 03/21/2001 | EP1083889A2 Method for treating neurodegenerative disorders |
| 03/21/2001 | EP1083888A1 MULTIBINDING AGENTS THAT MODULATE PPARgamma AND RXR RECEPTORS |
| 03/21/2001 | CN1288382A Sea cucumber carotenoid lipid fraction products and method of use |
| 03/21/2001 | CN1288378A Celecoxib compositions |
| 03/20/2001 | US6204241 Polypeptides found in vertebrate species, which polypeptides are mitogenic growth factors for glial cells, including schwann cells. |
| 03/15/2001 | WO2001018236A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 03/15/2001 | WO2001018204A1 Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby |
| 03/15/2001 | WO2001018172A2 Fibroblast growth factor-like polypeptides |
| 03/15/2001 | WO2001018049A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies |
| 03/15/2001 | WO2001018021A1 B7-like polynucleotides, polypeptides, and antibodies |
| 03/15/2001 | WO2001017596A1 Method of treating cardio pulmonary diseases with no group compounds |
| 03/15/2001 | WO2001017545A1 Remedies for nervous diseases |
| 03/15/2001 | DE19925668A1 Spleißosomprotein und seine Verwendung Spleißosomprotein and its use |
| 03/15/2001 | CA2389916A1 B7-like polynucleotides, polypeptides, and antibodies |
| 03/15/2001 | CA2384672A1 Steroid hormone receptor polynucleotides, polypeptides, and antibodies |
| 03/15/2001 | CA2383790A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 03/15/2001 | CA2383788A1 Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby |
| 03/15/2001 | CA2383774A1 Fibroblast growth factor-like polypeptides |
| 03/14/2001 | EP1082301A1 Ureas and carbamates of n-heterocyclic carboxylic acids and carboxylic acid isosteres |
| 03/14/2001 | EP1082289A1 Methods for identifying novel multimeric agents that modulate receptors |
| 03/14/2001 | EP1082110A1 Use of compounds for the elevation of pyruvate dehydrogenase activity |
| 03/14/2001 | CN1287555A N-oxides of heterocyclic compounds with TNF and PDE IV inhibiting activity |
| 03/14/2001 | CN1287487A Aminophenoxyacetic acid derivatives as neuroprotectants and pharmaceutical composition containing the same |
| 03/14/2001 | CN1063072C Tung oil plaster for reinforcing muscles and strengthening bones and its preparing method |
| 03/13/2001 | US6201130 N-arylsulfonylamino acid omega-amides |
| 03/13/2001 | US6201020 Effective poly(adenosine 5'-diphospho-ribose) polymerase (parp) inhibitor for treatment of tissue damage by necrosis or apoptosis; side effect reduction |
| 03/13/2001 | US6200599 Ortho ester lipids |
| 03/08/2001 | WO2001016345A2 Sequence-specific dna recombination in eukaryotic cells |
| 03/08/2001 | WO2001016304A2 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |
| 03/08/2001 | WO2001016137A1 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 03/08/2001 | WO2001016134A1 Selective antagonists of a2b adenosine receptors |
| 03/08/2001 | WO2001016121A1 Heterocyclic compounds and methods of use thereof |
| 03/08/2001 | WO2001015700A1 POLYMORPHS OF N-METHYL-N-(3-{3-[2-THIENYLCARBONYL]-PYRAZOL-[1,5-α]-PYRIMIDIN -7-YL }PHENYL )ACETAMIDE AND COMPOSITIONS AND METHODS RELATED THERETO |
| 03/08/2001 | WO2000059448A3 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |
| 03/08/2001 | WO2000050872A3 A system for cell-based screening |
| 03/08/2001 | WO2000039283A8 Use of cd40 engagement to alter t cell receptor usage |
| 03/08/2001 | WO1999063930A8 Novel angiotensin receptor modulators and their uses |
| 03/07/2001 | EP1081137A1 Selective inhibitors of aggrecanase in osteoarthritis treatment |
| 03/07/2001 | EP1080370A1 Identification of broadly reactive dr restricted epitopes |
| 03/07/2001 | EP1080087A1 Novel 2-alkyl substituted imidazole compounds |
| 03/07/2001 | EP1080083A1 Novel heterocyclically substituted amides with cysteine protease-inhibiting effect |
| 03/07/2001 | EP1080080A1 Novel therapeutic agents that modulate neurokinin receptors |
| 03/07/2001 | EP1080074A1 New heterocyclically substituted amides, their production and their use |
| 03/06/2001 | US6197323 Medicinal preparation containing a lipophilic inert gas |
| 03/06/2001 | US6197294 Cells containing recombinant polynucleotides coding for cell surface molecules that, when expressed in the cell, result in rejection of the cell by host cell by host immune system; useful for gene therapy |
| 03/01/2001 | WO2001014570A1 Activatable recombinant neurotoxins |
| 03/01/2001 | WO2001014557A1 Pd-1, a receptor for b7-4, and uses therefor |
| 03/01/2001 | WO2001014415A2 Egfh2 genes and gene products |
| 03/01/2001 | WO2001014375A1 Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives |
| 03/01/2001 | WO2001014372A2 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent |
| 03/01/2001 | WO2001014371A1 N-heterocyclic derivatives as nos inhibitors |
| 03/01/2001 | WO2001013916A1 Drugs inhibiting cell death |
| 03/01/2001 | WO2000075365A3 COMPOUNDS AND METHODS TO ENHANCE rAAV TRANSDUCTION |
| 03/01/2001 | DE19941186A1 Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen Sequence-specific DNA recombination in eukaryotic cells |
| 03/01/2001 | CA2383456A1 Pd-1, a receptor for b7-4, and uses therefor |
| 03/01/2001 | CA2380457A1 Activatable recombinant neurotoxins |
| 03/01/2001 | CA2376293A1 Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives |
| 02/28/2001 | EP1077946A1 Fused tricyclic compounds which inhibit parp activity |
| 02/28/2001 | EP1077944A1 Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| 02/28/2001 | EP1077943A1 Heterocyclic inhibitors of p38 |
| 02/28/2001 | CN1285836A 3'-epimeric k-252a derivatives |
| 02/27/2001 | US6194458 1-(2-methoxyphenyl)-1-oxo-2-aza-(s)-4-i-butyl-4-phenylbutane, for example; treating various conditions including transplantation rejection of organs or tissues in a patient; immunosuppressant compositions |
| 02/22/2001 | WO2001012819A2 Protein phosphatases and diagnosis and treatment of phosphatase-related disorders |
| 02/22/2001 | WO2001012790A2 Isomerase proteins |
| 02/22/2001 | WO2001012775A2 25 human secreted proteins |
| 02/22/2001 | WO2001012670A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | WO2001012633A1 Water soluble sdz-rad esters |
| 02/22/2001 | WO2001012622A1 Piperidine and pyrrolidine derivatives displaying neuronal activity |
| 02/22/2001 | WO2001012621A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 02/22/2001 | WO2001012598A2 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 02/22/2001 | WO2001012592A2 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/22/2001 | WO2001012233A2 Sustained release formulation of a peptide |
| 02/22/2001 | WO2001012202A2 Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
| 02/22/2001 | WO2001012175A1 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 02/22/2001 | WO2001012174A1 Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof |
| 02/22/2001 | WO2001012170A2 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| 02/22/2001 | WO2001012155A1 Compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| 02/22/2001 | WO2000055126A3 N-cyanomethylamides as protease inhibitors |
| 02/22/2001 | WO1999063996A8 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht2 receptors |
| 02/22/2001 | CA2689735A1 Compositions comprising modafinil for treatment of fatigue associated with multiple sclerosis |
| 02/22/2001 | CA2391319A1 Water soluble sdz-rad esters |
| 02/22/2001 | CA2385431A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | CA2383268A1 Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |